Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Frequently asked questions
What sector does Jasper Therapeutics Inc (JSPRW) operate in?
Jasper Therapeutics Inc belongs to the Healthcare sector and operates in the industry.
What is Jasper Therapeutics Inc (JSPRW) current stock price?
As of the latest data, Jasper Therapeutics Inc stock price is $0.00, with a previous close of $0.00. Jasper Therapeutics Inc lost -$0.00 in the last trading session, representing a -84.62% loss.
What is Jasper Therapeutics Inc (JSPRW) current market capitalization?
Jasper Therapeutics Inc market cap is approximately 5.74 thousand.
What is Jasper Therapeutics Inc (JSPRW) Earnings Per Share (EPS)?
The trailing EPS is -$3.84.
What is Jasper Therapeutics Inc (JSPRW) EBITDA?
Jasper Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.74 million.
Does Jasper Therapeutics Inc (JSPRW) pay dividends?
No. Jasper Therapeutics Inc does not pay a dividend.
What is Jasper Therapeutics Inc (JSPRW) beta (volatility) score?
Jasper Therapeutics Inc has a beta of 3.042, indicating very high volatility compared to the market.
